Stock TRIL TRILLIUM THERAPEUTICS
Add to a list
To use this feature you must be a member
Log inSign up
Inactive Instrument

All News Trillium Therapeutics

Equities

TRIL

CA89620X5064

All News

Search
See the results
Unlock all the news: Be the first to know and act before the market!
100% Free Registration
TCR2 Therapeutics Appoints Chief Business and Strategy Officer
MT
Pfizer Deploying Some of Its Covid Cash in Arena Deal -- Analysis
DJ
Pfizer Eyes Enhanced Immuno-Inflammatory Disease Expertise With $6.7 Billion Arena Pharmaceuticals Takeover
MT
Trillium Therapeutics Inc.(TSX:TRIL) dropped from S&P Global BMI Index
CI
Trillium Therapeutics : Pfizer Completes Acquisition of Trillium Therapeutics - Form 8-K
PU
Pfizer Completes $2.22 Billion Trillium Therapeutics Acquisition
MT
TRILLIUM THERAPEUTICS INC. : Completion of Acquisition or Disposition of Assets, Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing, Material Modification to Rights of Security Holders, Changes in Control or Registrant, Change in Directors or Principal Officers, Other Events, Financial Statements and Exhibits (form 8-K)
AQ
Trillium Therapeutics Inc. Announces Executive Changes
CI
Trillium Therapeutics Inc. Announces Resignation of Jan Skvarka as Chief Executive Officer
CI
Trillium Therapeutics Inc. Announces Cessation of James Parsons as Chief Financial Officer
CI
Benchmark Downgrades Trillium Therapeutics to Hold From Buy
MT
Pfizer-Trillium Therapeutics $2.26 Billion Deal Secures Canada, US Approval
MT
Trillium Therapeutics Inc.(NasdaqCM:TRIL) dropped from NASDAQ Composite Index
CI
Pfizer Inc. completed the acquisition of remaining 97.8% stake in Trillium Therapeutics Inc. from New Enterprise Associates 16, L.P., a fund managed by New Enterprise Associates, Inc., Avoro Capital Advisors LLC, RA Capital Healthcare Fund, L.P., a fund managed by RA Capital Management, L.P. and others.
CI
TRILLIUM THERAPEUTICS INC. : Other Events (form 8-K)
AQ
Trillium: Q3 Earnings Snapshot
AQ
TRILLIUM THERAPEUTICS INC. Management's Discussion and Analysis of Financial Condition and Results of Operations (form 10-Q)
AQ
Trillium Therapeutics Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2021
CI
North American Morning Briefing : Stock Futures -3-
DJ
Trillium Therapeutics Receives Final Court Order Approving Arrangement - Form 8-K
PU
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. TRIL Stock
  4. News Trillium Therapeutics